RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) Sees Significant Decrease in Short Interest

RCN Pareto Strategic Allocation ETF (NYSEARCA:PRTO) saw a significant drop in short interest in June. As of June 30th, there was short interest totaling 338 shares, a drop of 82.9% from the June 15th total of 1,978 shares. Based on an average daily trading volume, of 503 shares, the short-interest ratio is presently 0.7 days. Approximately 0.0% of the shares of the stock are short sold.

RCN Pareto Strategic Allocation ETF Stock Down 1.3%

RCN Pareto Strategic Allocation ETF stock traded down $0.35 during midday trading on Monday, hitting $27.23. 6 shares of the company’s stock were exchanged. The stock has a market cap of $603.93 million, a price-to-earnings ratio of -28.36 and a beta of 0.60. RCN Pareto Strategic Allocation ETF has a 52-week low of $24.68 and a 52-week high of $28.16.

Proteon Therapeutics was a biopharmaceutical company focused on developing treatments for patients with kidney and vascular diseases. The company’s research and development efforts centered on therapies designed to address severe and life-threatening conditions, particularly those related to renal disease and vascular access for hemodialysis patients.

One of Proteon Therapeutics’ best-known product candidates was vonapanitase, an investigational enzyme developed to improve vascular access outcomes in patients with end-stage renal disease who require hemodialysis.